<!DOCTYPE html>
<html lang="en"><head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<link href="https://cdn-icons-png.flaticon.com/512/4021/4021693.png" rel="icon"/>
<link href="../style.css" rel="stylesheet"/>
<link href="https://fonts.googleapis.com" rel="preconnect"/>
<link crossorigin="" href="https://fonts.gstatic.com" rel="preconnect"/>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600&amp;family=Space+Mono:wght@400;700&amp;display=swap" rel="stylesheet"/>
<title>TAK-653</title>
</head><body><main class="container"><header class="site-header">
<h1 class="logo"><a href="../index.html">r/anhedonia</a></h1>
<p class="subtitle">Personal Wiki</p>
</header><nav style="margin-bottom: 20px;"><a href="../actions.html">← Back to Personal Wiki</a></nav><section class="card"><h2>TAK-653</h2><ul>
<li><img src="https://upload.wikimedia.org/wikipedia/commons/1/15/TAK-653.svg"/></li>
<li>Also named Osavampator and NBI-1065845.</li>
<li>Selective positive allosteric modulator (PAM) of the AMPA receptor.</li>
<li>Potentiate the effects of agonists at the main site of the AMPA receptor by slowing the rate of desensitization and internalization of the receptor.</li>
<li>Terminal half-life is 33.1–47.8 hours.</li>
<li>Possesses minimal direct AMPA agonist properties.</li>
<li>Provides a 419-fold safety margin against convulsions relative to therapeutic doses in rats.</li>
</ul></section><footer class="site-footer">
<p><a href="../index.html">← Back to Home</a></p>
</footer></main></body></html>